Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis

Brief description of study

The overall purpose of this one year extension is to allow further treatment of patients who
have already completed the core study, and to enable collection of long term efficacy and
safety data.
Patients will continue to receive Exjade at the dose they received at the end of the core
study.